Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - perindopril erbumine -

Israel - engelsk - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 150 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Israel - engelsk - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 75 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; magnesium stearate; isomalt; colloidal anhydrous silica; hypromellose; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; isomalt; magnesium stearate; hypromellose; brilliant blue fcf aluminium lake; titanium dioxide; hyprolose; colloidal anhydrous silica; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg - tablet, film coated - excipient ingredients: iron oxide yellow; colloidal anhydrous silica; hypromellose; isomalt; titanium dioxide; macrogol 8000; magnesium stearate; brilliant blue fcf aluminium lake; hyprolose - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

USA - engelsk - NLM (National Library of Medicine)

professional complementary health formulas - asafoetida 8x kalmia latifolia 8x causticum 10x colchicum autumnale 10x ferrum metallicum 10x gnaphalium polycephalum 10x lithium benzoicum 10x mercurius praecipitatus ruber 10x rhus toxicodendron 10x spiraea ulmaria 10x - for the temporary relief of minor pain, stiffness, or inflammation of joints or connective tissue.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.